The US Food and Drug Administration has approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform from Johnson & Johnson, an integrated catheter ablation system that enables electrophysiologists to deliver both pulsed field and radiofrequency energy through a single catheter, according to a press release from the company.

The platform is built on the THERMOCOOL SMARTTOUCH SF catheter platform, which Johnson & Johnson said has been used to treat more than one million patients in the US. According to the company, the newly approved platform integrates pulsed field and radiofrequency energy delivery into a single catheter.

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform is integrated with the CARTO ecosystem, including mapping, imaging, and pulsed field index guidance. According to Johnson & Johnson, the platform helps physicians deliver energy with precise contact force and allows use of radiofrequency or pulsed field energy based on patient anatomy and case complexity.

Johnson & Johnson said the first US procedures using the platform are expected to begin this summer as part of a phased commercial rollout.

“The Dual Energy THERMOCOOL SMARTTOUCH SF Platform gives electrophysiologists the choice to use RF [radiofrequency] or PF [pulsed field] energy based on the needs of each procedure. Having both capabilities integrated in the CARTO system can help us adapt our approach for more complex cases and plan procedures with greater confidence,” said Dhanunjaya Lakkireddy, MD, FHRS, MBA, Executive Medical Director of The Kansas City Heart Rhythm Institute.

The press release states that Dhanunjaya Lakkireddy, MD, FHRS, MBA, serves as a consultant for Johnson & Johnson and was not compensated for his contribution to the announcement.

Source: Johnson & Johnson